Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer

International Journal of Clinical Oncology

Volumn 14, Issue 1, 2009, Pages 48-52

  Ono, Makiko ^a   Ando, Masashi ^a   Yunokawa, Mayu ^a   Nakano, Eriko ^a   Yonemori, Kan ^a   Matsumoto, Koji ^b   Kouno, Tsutomu ^a   Shimizu, Chikako ^a   Tamura, Kenji ^a   Katsumata, Noriyuki ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b HYOGO CANCER CENTER   (Japan)

Author keywords

Brain metastases; HER2 overexpressing breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RISK; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE PREDISPOSITION; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE NEU; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; TREATMENT DURATION;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; UP-REGULATION;

EID: 60649103431     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0797-8     Document Type: Article

References (20)

1. D.J. Slamon G.M. Clark S.G. Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182
2. D.J. Slamon W. Gololphin L.A. Jones 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712
3. M.F. Press L. Bernstein P.A. Thomas 1997 HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 2894 2904
4. P. Carter L. Presta C.M. Gorman 1992 Humanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285 4289
5. D.J. Slamon B. Leyland-Jones S. Shak 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792
6. I. Smith M. Procter R.D. Gelber 2007 Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial Lancet 369 29 36
7. E.H. Romand E.A. Perez J. Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684
8. H. Joensuu P.L. Kellokumpu-Lehtinen P. Bono 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820
9. K.D. Miller T. Weathers L.G. Haney 2003 Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival Ann Oncol 14 1072 1077
10. A.J. Clayton S. Danson S. Jolly 2004 Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer Br J Cancer 91 639 643
11. J.C. Bendell S.M. Domchek H.J. Burstein 2003 Central nervous system metastases in women who receive transtuzumab-based therapy for metastatic breast carcinoma Cancer 97 2972 2977
12. T. Yau C. Swanton S. Chua 2006 Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab Acta Oncol 45 196 201
13. R. Lai C.T. Dang M.G. Malkin 2004 The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma Cancer 101 810 816
14. E. Shmueli N. Wigler M. Inbar 2004 Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment Eur J Cancer 40 379 382
15. Z. Gabos R. Sinha J. Hanson 2006 Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer J Clin Oncol 24 5658 5663
16. K. Slimane F. Andre S. Delaloge 2004 Risk factors for brain relapse in patients with metastatic breast cancer Ann Oncol 15 1640 1644
17. H.J. Stemmler S. Kahlert W. Siekiera 2006 Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer Breast 15 219 225
18. B.C. Pestalozzi D. Zahrieh K.N. Price 2006 Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) Ann Oncol 17 935 944
19. B.C. Pestalozzi S. Brignoli 2000 Trastuzumab in CSF J Clin Oncol 18 2350 2351
20. N.U. Lin L.A. Carey M.C. Liu 2006 Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer J Clin Oncol 24 18Suppl 503